Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1990 Jul;58(7):2367–2374. doi: 10.1128/iai.58.7.2367-2374.1990

Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A.

A Fattom 1, R Schneerson 1, S C Szu 1, W F Vann 1, J Shiloach 1, W W Karakawa 1, J B Robbins 1
PMCID: PMC258821  PMID: 2114365

Abstract

Epidemiological, serological and in vitro phagocytosis experiments provide evidence that the newly discovered type 5 and type 8 capsular polysaccharides (CPs) are both virulence factors and protective antigens for bacteremia caused by Staphylococcus aureus. Neither type 5 nor type 8 CP elicited serum antibodies when injected into mice. These two CPs were bound to Pseudomonas aeruginosa exotoxin A (ETA) to form conjugates by using the synthetic scheme devised for the CP (Vi) of Salmonella typhi and of pneumococcus type 12F (A. Fattom, W. F. Vann, S. C. Szu, A. Sutton, X. Li, D. Bryla, G. Schiffman, J. B. Robbins, and R. Schneerson, Infect. Immun. 56:2292-2298, 1988; S. C. Szu, A. L. Stone, J. D. Robbins, R. Schneerson, and J. B. Robbins, J. Exp. Med. 166:1510-1524, 1987). Both S. aureus CP-ETA conjugates elicited a rise in CP antibodies. As components of conjugates, both S. aureus CPs acquired T-cell-dependent properties, as shown by their ability to respond to carrier priming and to stimulate booster responses. The conjugate-induced antibodies facilitated type-specific opsonization of S. aureus by human polymorphonuclear leukocytes. The conjugates also induced ETA antibodies which neutralized the native toxin in vitro. Clinical studies of these two conjugates for active or passive immunization of patients at risk for S. aureus bacteremia are planned.

Full text

PDF
2367

Images in this article

2370Image
on p.2370

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albus A., Fournier J. M., Wolz C., Boutonnier A., Ranke M., Høiby N., Hochkeppel H., Döring G. Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis. J Clin Microbiol. 1988 Dec;26(12):2505–2509. doi: 10.1128/jcm.26.12.2505-2509.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arbeit R. D., Dunn R. M. Expression of capsular polysaccharide during experimental focal infection with Staphylococcus aureus. J Infect Dis. 1987 Dec;156(6):947–952. doi: 10.1093/infdis/156.6.947. [DOI] [PubMed] [Google Scholar]
  3. Arbeit R. D., Karakawa W. W., Vann W. F., Robbins J. B. Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis. 1984 Apr;2(2):85–91. doi: 10.1016/0732-8893(84)90002-6. [DOI] [PubMed] [Google Scholar]
  4. Arbeit R. D., Nelles M. J. Capsular polysaccharide antigenemia in rats with experimental endocarditis due to Staphylococcus aureus. J Infect Dis. 1987 Feb;155(2):242–246. doi: 10.1093/infdis/155.2.242. [DOI] [PubMed] [Google Scholar]
  5. Blumentals I. I., Kelly R. M., Gorziglia M., Kaufman J. B., Shiloach J. Development of a defined medium and two-step culturing method for improved exotoxin A yields from Pseudomonas aeruginosa. Appl Environ Microbiol. 1987 Sep;53(9):2013–2020. doi: 10.1128/aem.53.9.2013-2020.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Boutonnier A., Nato F., Bouvet A., Lebrun L., Audurier A., Mazie J. C., Fournier J. M. Direct testing of blood culture for detection of the serotype 5 and 8 capsular polysaccharides of Staphylococcus aureus. J Clin Microbiol. 1989 May;27(5):989–993. doi: 10.1128/jcm.27.5.989-993.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Brumfitt W., Hamilton-Miller J. Methicillin-resistant Staphylococcus aureus. N Engl J Med. 1989 May 4;320(18):1188–1196. doi: 10.1056/NEJM198905043201806. [DOI] [PubMed] [Google Scholar]
  8. Carlsson J., Drevin H., Axén R. Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent. Biochem J. 1978 Sep 1;173(3):723–737. doi: 10.1042/bj1730723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chaudhary V. K., Queen C., Junghans R. P., Waldmann T. A., FitzGerald D. J., Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature. 1989 Jun 1;339(6223):394–397. doi: 10.1038/339394a0. [DOI] [PubMed] [Google Scholar]
  10. Cryz S. J., Jr, Furer E., Sadoff J. C., Germanier R. Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine. Infect Immun. 1986 Apr;52(1):161–165. doi: 10.1128/iai.52.1.161-165.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dobkin J. F., Miller M. H., Steigbigel N. H. Septicemia in patients on chronic hemodialysis. Ann Intern Med. 1978 Jan;88(1):28–33. doi: 10.7326/0003-4819-88-1-28. [DOI] [PubMed] [Google Scholar]
  12. Fattom A., Lue C., Szu S. C., Mestecky J., Schiffman G., Bryla D., Vann W. F., Watson D., Kimzey L. M., Robbins J. B. Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoid. Infect Immun. 1990 Jul;58(7):2309–2312. doi: 10.1128/iai.58.7.2309-2312.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fattom A., Vann W. F., Szu S. C., Sutton A., Li X., Bryla D., Schiffman G., Robbins J. B., Schneerson R. Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates. Infect Immun. 1988 Sep;56(9):2292–2298. doi: 10.1128/iai.56.9.2292-2298.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fournier J. M., Bouvet A., Boutonnier A., Audurier A., Goldstein F., Pierre J., Bure A., Lebrun L., Hochkeppel H. K. Predominance of capsular polysaccharide type 5 among oxacillin-resistant Staphylococcus aureus. J Clin Microbiol. 1987 Oct;25(10):1932–1933. doi: 10.1128/jcm.25.10.1932-1933.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fournier J. M., Hannon K., Moreau M., Karakawa W. W., Vann W. F. Isolation of type 5 capsular polysaccharide from Staphylococcus aureus. Ann Inst Pasteur Microbiol. 1987 Sep-Oct;138(5):561–567. doi: 10.1016/0769-2609(87)90041-x. [DOI] [PubMed] [Google Scholar]
  16. Fournier J. M., Vann W. F., Karakawa W. W. Purification and characterization of Staphylococcus aureus type 8 capsular polysaccharide. Infect Immun. 1984 Jul;45(1):87–93. doi: 10.1128/iai.45.1.87-93.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Francioli P., Masur H. Complications of Staphylococcus aureus bacteremia. Occurrence in patients undergoing long-term hemodialysis. Arch Intern Med. 1982 Sep;142(9):1655–1658. [PubMed] [Google Scholar]
  18. HANESSIAN S., HASKELL T. H. STRUCTURAL STUDIES ON STAPHYLOCOCCAL POLYSACCHARIDE ANTIGEN. J Biol Chem. 1964 Sep;239:2758–2764. [PubMed] [Google Scholar]
  19. Hochkeppel H. K., Braun D. G., Vischer W., Imm A., Sutter S., Staeubli U., Guggenheim R., Kaplan E. L., Boutonnier A., Fournier J. M. Serotyping and electron microscopy studies of Staphylococcus aureus clinical isolates with monoclonal antibodies to capsular polysaccharide types 5 and 8. J Clin Microbiol. 1987 Mar;25(3):526–530. doi: 10.1128/jcm.25.3.526-530.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Iglewski B. H., Sadoff J. C. Toxin inhibitors of protein synthesis: production, purification, and assay of Pseudomonas aeruginosa toxin A. Methods Enzymol. 1979;60:780–793. doi: 10.1016/s0076-6879(79)60071-x. [DOI] [PubMed] [Google Scholar]
  21. Ivatt R. J., Gilvarg C. Molecular structure of the teichuronic acid of Bacillus megaterium. Biochemistry. 1978 Sep 19;17(19):3997–4003. doi: 10.1021/bi00612a019. [DOI] [PubMed] [Google Scholar]
  22. Karakawa W. W., Fournier J. M., Vann W. F., Arbeit R., Schneerson R. S., Robbins J. B. Method for the serological typing of the capsular polysaccharides of Staphylococcus aureus. J Clin Microbiol. 1985 Sep;22(3):445–447. doi: 10.1128/jcm.22.3.445-447.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Karakawa W. W., Kane J. A. Characterization of the surface antigens of Staphylococcus aureus, strain K-93M. J Immunol. 1972 May;108(5):1199–1208. [PubMed] [Google Scholar]
  24. Karakawa W. W., Sutton A., Schneerson R., Karpas A., Vann W. F. Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun. 1988 May;56(5):1090–1095. doi: 10.1128/iai.56.5.1090-1095.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Karakawa W. W., Young D. A. Immunochemical study of diverse surface antigens of a Staphylococcus aureus isolate from an osteomyelitis patient and their role in in vitro phagocytosis. J Clin Microbiol. 1979 Mar;9(3):399–408. doi: 10.1128/jcm.9.3.399-408.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. King B. F., Wilkinson B. J. Binding of human immunoglobulin G to protein A in encapsulated Staphylococcus aureus. Infect Immun. 1981 Sep;33(3):666–672. doi: 10.1128/iai.33.3.666-672.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Lee J. C., Betley M. J., Hopkins C. A., Perez N. E., Pier G. B. Virulence studies, in mice, of transposon-induced mutants of Staphylococcus aureus differing in capsule size. J Infect Dis. 1987 Nov;156(5):741–750. doi: 10.1093/infdis/156.5.741. [DOI] [PubMed] [Google Scholar]
  28. Liau D. F., Hash J. H. Structural analysis of the surface polysaccharide of Staphylococcus aureus M. J Bacteriol. 1977 Jul;131(1):194–200. doi: 10.1128/jb.131.1.194-200.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. MORSE S. I. DISTRIBUTION OF A SURFACE ANTIGEN OF STAPHYLOCOCCUS AUREUS. Nature. 1963 Dec 14;200:1126–1127. doi: 10.1038/2001126a0. [DOI] [PubMed] [Google Scholar]
  30. Madshus I. H., Collier R. J. Effects of eliminating a disulfide bridge within domain II of Pseudomonas aeruginosa exotoxin A. Infect Immun. 1989 Jul;57(7):1873–1878. doi: 10.1128/iai.57.7.1873-1878.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. McGowan J. E., Jr, Barnes M. W., Finland M. Bacteremia at Boston City Hospital: Occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases. J Infect Dis. 1975 Sep;132(3):316–335. doi: 10.1093/infdis/132.3.316. [DOI] [PubMed] [Google Scholar]
  32. Melly M. A., McGee Z. A., Horn R. G., Morris F., Glick A. D. An electron microscopic India ink technique for demonstrating capsules on microorganisms: studies with Streptococcus pneumoniae, Staphylococcus aureus, and Neisseria gonorrhoeae. J Infect Dis. 1979 Oct;140(4):605–609. doi: 10.1093/infdis/140.4.605. [DOI] [PubMed] [Google Scholar]
  33. Murthy S. V., Melly M. A., Harris T. M., Hellerqvist C. G., Hash J. H. The repeating sequence of the capsular polysaccharide of Staphylococcus aureus M. Carbohydr Res. 1983 Jun 16;117:113–123. doi: 10.1016/0008-6215(83)88080-x. [DOI] [PubMed] [Google Scholar]
  34. Nelles M. J., Niswander C. A., Karakawa W. W., Vann W. F., Arbeit R. D. Reactivity of type-specific monoclonal antibodies with Staphylococcus aureus clinical isolates and purified capsular polysaccharide. Infect Immun. 1985 Jul;49(1):14–18. doi: 10.1128/iai.49.1.14-18.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Nolan C. M., Beaty H. N. Staphylococcus aureus bacteremia. Current clinical patterns. Am J Med. 1976 Apr;60(4):495–500. doi: 10.1016/0002-9343(76)90715-4. [DOI] [PubMed] [Google Scholar]
  36. Peterson P. K., Wilkinson B. J., Kim Y., Schmeling D., Douglas S. D., Quie P. G., Verhoef J. The key role of peptidoglycan in the opsonization of Staphylococcus aureus. J Clin Invest. 1978 Mar;61(3):597–609. doi: 10.1172/JCI108971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Peterson P. K., Wilkinson B. J., Kim Y., Schmeling D., Quie P. G. Influence of encapsulation on staphylococcal opsonization and phagocytosis by human polymorphonuclear leukocytes. Infect Immun. 1978 Mar;19(3):943–949. doi: 10.1128/iai.19.3.943-949.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Pollack M., Callahan L. T., 3rd, Taylor N. S. Neutralizing antibody to Pseudomonas aeruginosa exotoxin in human sera: evidence for in vivo toxin production during infection. Infect Immun. 1976 Oct;14(4):942–947. doi: 10.1128/iai.14.4.942-947.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Pollack M., Young L. S. Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest. 1979 Feb;63(2):276–286. doi: 10.1172/JCI109300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Schneerson R., Barrera O., Sutton A., Robbins J. B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med. 1980 Aug 1;152(2):361–376. doi: 10.1084/jem.152.2.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Sheagren J. N. Staphylococcus aureus. The persistent pathogen (first of two parts). N Engl J Med. 1984 May 24;310(21):1368–1373. doi: 10.1056/NEJM198405243102107. [DOI] [PubMed] [Google Scholar]
  42. Sompolinsky D., Samra Z., Karakawa W. W., Vann W. F., Schneerson R., Malik Z. Encapsulation and capsular types in isolates of Staphylococcus aureus from different sources and relationship to phage types. J Clin Microbiol. 1985 Nov;22(5):828–834. doi: 10.1128/jcm.22.5.828-834.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Sutton A., Vann W. F., Karpas A. B., Stein K. E., Schneerson R. An avidin-biotin based ELISA for quantitation of antibody to bacterial polysaccharides. J Immunol Methods. 1985 Oct 10;82(2):215–224. doi: 10.1016/0022-1759(85)90353-9. [DOI] [PubMed] [Google Scholar]
  44. Szu S. C., Stone A. L., Robbins J. D., Schneerson R., Robbins J. B. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med. 1987 Nov 1;166(5):1510–1524. doi: 10.1084/jem.166.5.1510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Wu T. C., Park J. T. Chemical characterization of a new surface antigenic polysaccharide from a mutant of Staphylococcus aureus. J Bacteriol. 1971 Nov;108(2):874–884. doi: 10.1128/jb.108.2.874-884.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Yoshida K., Smith M. R., Naito Y. Biological and Immunological Properties of Encapsulated Strains of Staphylococcus aureus from Human Sources. Infect Immun. 1970 Nov;2(5):528–532. doi: 10.1128/iai.2.5.528-532.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Yu V. L., Goetz A., Wagener M., Smith P. B., Rihs J. D., Hanchett J., Zuravleff J. J. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med. 1986 Jul 10;315(2):91–96. doi: 10.1056/NEJM198607103150204. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES